ALZHEIMER’S DISEASE
Recruiting for Phase 2 Study
We are currently recruiting for our Phase 2 study to evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate Alzheimer’s disease (AD).
Trial initiation received approval in June 2024 from the Australia Human Research Ethics Committee.
Spinogenix contact for questions regarding clinical trial:
info@spinogenix.com
Clinical Trials are Open in Australia:
NCT06427668
Status: Recruiting
Locations
St Vincent’s Hospital, Sydney, NSW, Australia
Contact: Valerie Bramah
valerie.bramah@svha.org.au
Principal Investigator, Bruce Brew, MBBS MD DSc
Flinders Medical Center, Adelaide, SA, Australia
Contact: Aimee Cayzer at Flinders Medical Center
RAPMTU@sa.gov.au
Principal Investigator, Lauren Priest, MBBS
For additional information, visit ClinicalTrials.gov
